Silver Book Fact

A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took alendronate. The study followed about 1,200 women with low bone mass for over a year.

Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass Treated With 6-monthly Denosumab or Weekly Alendronate. http://www.rheumatology.org/press/2008/2008_press_14.asp. Published October 2008

Reference

Title
Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass Treated With 6-monthly Denosumab or Weekly Alendronate
Publication Date
Published October 2008
Authors
Deal, Chad, Jacques Brown, Robert Recker, Richard Prince, Douglas Kiel, Jose Ã?lvaro-Gracia, Luiz de Gregorio, Peyman Hadji, Lorenz Hofbauer, Huei Wang, Matthew Austin, Richard Newmark, Cesar Libanati, Rachel Wagman, Javier San Martin, Henry Bone
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.